Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1/2 1Phase 1 1

Status

Active not recruiting 5Recruiting 2Withdrawn 1

Sponsor Class

OTHER 8

Study Type

Interventional 8

Sponsor

Cancer Type

Breast 8

Conditions

Carcinoma, Transitional Cell 16Urinary Bladder Neoplasms 15Carcinoma, Merkel Cell 10Neoplasm Metastasis 8Carcinoma, Renal Cell 8Breast Neoplasms 8Neoplasms 6Triple Negative Breast Neoplasms 5Melanoma 5Ureteral Neoplasms 4Stomach Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Ovarian Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Urethral Neoplasms 3Skin Neoplasms 3Prostatic Neoplasms 3Colorectal Neoplasms 3Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Neuroendocrine Tumors 2Head and Neck Neoplasms 2Endometrial Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Hepatocellular 2Uveal Melanoma 1Urothelial Cancer 1Turcot syndrome 1Thymoma 1

Interventions

Fulvestrant 125Trastuzumab 114Paclitaxel 113Letrozole 108pembrolizumab 79pertuzumab 75palbociclib 75Capecitabine 72Anastrozole 72Cyclophosphamide 70Carboplatin 67abemaciclib 64exemestane 63Tamoxifen 63ribociclib 60trastuzumab deruxtecan 57Surveys and Questionnaires 51Specimen Handling 50Radiotherapy 49Docetaxel 49Magnetic Resonance Spectroscopy 48Blood Specimen Collection 40olaparib 39Standard of Care 36Biopsy 33sacituzumab govitecan 31130-nm albumin-bound paclitaxel 31Doxorubicin 30Exercise 29eribulin 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

8 trials
RecentStart dateEnrollment
Breast Neoplasms × avelumab × 1 year × Clear all
NCT03971409 2026-04-17

InCITe

University of California, San Francisco

Phase 2 Active not recruiting
145 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03964532 2026-04-09

TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer

Georgetown University

Phase 1/2 Active not recruiting
24 enrolled
Breast

Breast Neoplasms

NCT04841148 2026-04-09

PALAVY

Abramson Cancer Center at Penn Medicine

Phase 2 Recruiting
96 enrolled
Breast

Breast Neoplasms, Neoplasm, Residual

NCT04360941 2026-04-06

PAveMenT

Royal Marsden NHS Foundation Trust

Phase 1 Recruiting
45 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03573648 2026-03-19

ImmunoADAPT

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Active not recruiting
33 enrolled
Breast

Breast Neoplasms

NCT04188119 2025-12-08

IMpALA

The Christie NHS Foundation Trust

Phase 2 Withdrawn
Breast

Breast Neoplasms

NCT03147287 2025-09-30

Palbociclib After CDK and Endocrine Therapy (PACE)

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
220 enrolled 11 charts
Breast

Breast Neoplasms

NCT03414658 2025-07-02

The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
100 enrolled 15 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡